Drug used in supraventricular tachycardia
Drug used in supraventricular tachycardia Supraventricular tachycardia (SVT) is a rapid heart rhythm originating above the ventricles, often causing symptoms such as palpitations, dizziness, shortness of breath, or even chest discomfort. Managing SVT effectively requires prompt and appropriate intervention, with pharmacologic therapy playing a crucial role in both acute and long-term settings. Several drugs are used in the treatment of SVT, each with specific mechanisms of action, indications, and potential side effects.
In the acute setting, the primary goal is to terminate the arrhythmia swiftly and safely. One of the most commonly used medications is adenosine. Adenosine acts quickly to temporarily block conduction through the atrioventricular (AV) node, which often halts the reentrant circuit responsible for SVT. Given its very short half-life—less than 10 seconds—adenosine provides rapid symptom relief and is administered via rapid IV push, often followed by a saline flush. Its high efficacy and safety profile make it the first-line pharmacologic agent in acute episodes, though it may cause transient flushing, chest discomfort, or brief pauses in heart rhythm. Drug used in supraventricular tachycardia
If adenosine is contraindicated or ineffective, other medications such as vagal maneuvers, beta-blockers, or calcium channel blockers may be employed. Vagal maneuvers stimulate the vagus nerve to slow AV nodal conduction, often providing immediate relief without medication. Beta-blockers like metoprolol or atenolol reduce sympathetic stimulation and slow conduction through the AV node, helping control the heart rate. Calcium channel blockers, particularly verapamil and diltiazem, are also effective in acutely terminating SVT by decreasing AV nodal conduction velocity. Drug used in supraventricular tachycardia
For longer-term management or in cases where episodes are recurrent, medications such as oral beta-blockers or calcium channel blockers may be prescribed. These drugs help prevent episodes by stabilizing the electrical conduction system of the heart. In some patients, antiarrhythmic drugs like flecainide or propafenone are utilized, especially when other therapies fail or are contraindicated.
In certain cases, especially when medication therapy is ineffective or not tolerated, catheter ablation may be considered. This procedure involves targeted destruction of the abnormal conduction pathway, often offering a potential cure for recurrent SVT. Drug used in supraventricular tachycardia
Drug used in supraventricular tachycardia It’s important to note that while these medications are generally safe when used appropriately, they require careful monitoring. Side effects can include hypotension, bradycardia, or adverse reactions specific to each drug. Therefore, the choice of drug depends on the patient’s overall health, the presence of other medical conditions, and the specific characteristics of their arrhythmia.
Overall, managing SVT with the appropriate drug therapy involves a comprehensive understanding of the pharmacology, patient-specific factors, and the clinical setting. Prompt recognition and treatment can significantly reduce risks and improve quality of life for individuals affected by this common arrhythmia. Drug used in supraventricular tachycardia
